He aha te tikanga o te "Maama"?
Karekau te kararehe e kawe i te huringa. E kore e whakawhanake i te mate a e kore e tukuna atu.
Alaskan Malamute Polyneuropathy (AMPN) is a genetic disorder that affects the nervous system of Alaskan Malamutes. A DNA test for AMPN can help dog owners identify whether their pets are carriers of this condition, which may lead to debilitating symptoms such as muscle weakness and impaired coordination. Early detection through DNA testing is crucial for managing the health of affected dogs, allowing for better care and informed breeding decisions. By knowing your dog's genetic status, you can take proactive steps to ensure a healthier life for your Alaskan Malamute. Don't wait—consider a DNA test today to safeguard your furry friend against AMPN. Protect your dog's well-being with this simple yet essential genetic screening.
Alaskan Malamute Polyneuropathy (AMPN) is a genetic condition affecting the nervous system of Alaskan Malamutes. DNA testing for AMPN helps identify carriers and affected dogs, allowing breeders to make informed decisions to reduce the prevalence of this disorder. Symptoms may include muscle weakness and coordination issues, impacting the dog's quality of life. Early detection through genetic testing can aid in managing the condition effectively. Responsible breeding practices can help ensure healthier future generations of this beloved breed.
Kua whakauruhia tenei whakamatautau DNA mai i ta maatau kete Basic — he waahanga ano hoki o nga kete Basic, Standard, Advanced, Complete.
Tirohia nga Puka Whakamatau DNA →Alaskan Malamute Polyneuropathy (AMPN) is a hereditary neurological disorder that primarily affects Alaskan Malamutes, leading to a range of debilitating symptoms. This condition is characterized by the degeneration of peripheral nerves, which can result in significant mobility issues and impairments in the dog's overall quality of life.
Dogs affected by AMPN may exhibit a variety of symptoms, which can vary in severity. Common signs include muscle weakness, difficulty in walking or running, and a noticeable decrease in coordination. As the disease progresses, affected dogs may develop tremors, a wobbly gait, and muscle atrophy. These symptoms often manifest between the ages of 6 months and 2 years, although the onset can vary.
The condition is caused by a genetic mutation that affects the structure and function of nerve fibers. This mutation can be identified through a DNA test, which helps in diagnosing the condition before clinical signs become apparent. Understanding the genetic basis of AMPN is crucial for breeders and pet owners, as it aids in making informed decisions regarding breeding practices and the management of affected dogs.
DNA testing for AMPN plays a vital role in the early detection and management of the disease. By identifying carriers of the genetic mutation, breeders can take steps to avoid mating affected dogs, thereby reducing the incidence of the disorder in future generations. Moreover, knowing a dog’s genetic status can assist owners in making informed decisions about their pet’s care and potential lifestyle adjustments.
While there is currently no cure for AMPN, management strategies can significantly improve the quality of life for affected dogs. These may include physical therapy, pain management, and modifications to the dog's environment to accommodate mobility challenges. Regular veterinary check-ups are essential to monitor the condition and adjust treatment plans as needed.
Alaskan Malamute Polyneuropathy is a serious genetic condition that can severely impact the health and well-being of affected dogs. Through DNA testing, owners and breeders can take proactive steps in managing this disorder, ensuring that future generations of Alaskan Malamutes are healthier and less prone to AMPN. Understanding the implications of this condition is crucial for responsible breeding and compassionate care of affected dogs.
Karekau te kararehe e kawe i te huringa. E kore e whakawhanake i te mate a e kore e tukuna atu.
Kao. He hauora te kararehe engari ka taea e ia te tuku i te huringa ki tona uri.
E rua nga kape whakarereke. Ko nga tohu haumanu kei te tumanakohia te mate. Kaua e whakatipuria.
Ko etahi o nga mate he hononga-a-ira, no reira ka rereke o raatau korero i runga i te ira kararehe.
This DNA test detects the mutation associated with Alaskan Malamute Polyneuropathy (AMPN) in order to identify clear, carrier, or at-risk animals.
Ko te whakamatautau DNA ka awhina i nga kaiwhakawhanake ki te whakamahere i nga hononga haumaru ake me te whakaiti i te tupono ki te tuku i te huringa ki nga uri.
Ko te tikanga tuku iho mo tenei whakamatautau ko Autosomal Recessive.
This test analyses the mutation NDRG1 c.293G>T.
Ehara i te mea. Ko te whakamaoritanga ka whakawhirinaki ki te tauira tuku iho me te momo momo ira ka puta.
Bruun Camilla S, Jäderlund Karin H, Berendt Mette, Jensen Kristine B, Spodsberg Eva H, Gredal Hanne, Shelton G Diane, Mickelson James R, Minor Katie M, Lohi Hannes, Bjerkås Inge, Stigen Oyvind, Espenes Arild, Rohdin Cecilia, Edlund Rebecca, Ohlsson Jennie, Cizinauskas Sigitas, Leifsson Páll S, Drögemüller Cord, Moe Lars, Cirera Susanna, Fredholm Merete. A Gly98Val mutation in the N-Myc downstream regulated gene 1 (NDRG1) in Alaskan Malamutes with polyneuropathy. PLoS One. 2013;8(2):e54547. doi: 10.1371/journal.pone.0054547. Epub 2013 Feb 5.
To tūmataitinga, to whiringa
Ka whakamahi matou i nga pihikete whakahirahira hei whakahaere i te paetukutuku. Ko nga pihikete whiriwhiri (penei i nga kaiwhakarato ihirangi kua whakauruhia) kua monoa ma te taunoa ka whakahohea mena ka whakaae koe. Ka taea e koe te huri i to whiringa i nga wa katoa ma te whakamahi i te paatene "Pihikete".
E hiahiatia ana mo nga ahuatanga matua me te haumarutanga. Whakahohea i nga wa katoa.
Ka whakapai ake i nga ahuatanga penei i te penapena manakohanga, i nga taapiri kore-panui ranei.
Ka awhina tatou ki te mohio ki te whakamahinga o te waahi. Kua monoa e te taunoa.
Panuitanga / aroturuki puta noa i nga waahi (etahi riipene whakaata / mapi kua whakauruhia). Kua monoa e te taunoa.